Drug-induced liver injury associated with statins

Seminars in Liver Disease

Volumn 29, Issue 4, 2009, Pages 412-422

  Russo, Mark W ^a   Scobey, Martin ^a   Bonkovsky, Herbert L ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Autoimmune hepatitis; Hepatotoxicity; Hydroxymethylglutaryl coenzyme A reductase; Lipid lowering agents; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; AUTOANTIBODY; AZATHIOPRINE; BILIRUBIN; FLUINDOSTATIN; GLOBULIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFUSION FLUID; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PREDNISONE; RIFAMPICIN; SMOOTH MUSCLE ANTIBODY; UNSATURATED FATTY ACID; URSODEOXYCHOLIC ACID;

ABDOMINAL DISCOMFORT; ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTIBODY TITER; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; BODY MASS; CASE REPORT; CELL DEATH; CHOLESTATIC HEPATITIS; CHOLESTEROL BLOOD LEVEL; CHRONIC ACTIVE AUTOIMMUNE HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FAT INTAKE; FATIGUE; FEMALE; GALLSTONE; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERSOMNIA; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; LOW CARBOHYDRATE DIET; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; UPPER ABDOMINAL PAIN; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNITY; BIOLOGICAL MARKERS; BIOPSY; CHRONIC DISEASE; DRUG-INDUCED LIVER INJURY; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INDOLES; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PYRROLES; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70449096299     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0029-1240010     Document Type: Article

References (65)

1. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005 41 (4) 690-695
2. Horsmans Y, Desager J P., Harvengt C. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacol Toxicol 1990 67 (4) 336-339
3. Alvarez F, Berg P A., Bianchi F B. et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999 31 (5) 929-938
4. Geddes J A. Cholestatic jaundice associated with lovastatin (Mevacor) therapy. CMAJ 1990 143 (1) 13-14
5. McQueen M J. Cholestatic jaundice associated with lovastatin (Mevacor) therapy. CMAJ 1990 142 (8) 841-842
6. Ballar M, Campanini M, Catania E, Bordin G, Zaccala G, Monteverde A. Acute cholestatic hepatitis during simvastatin administration. Recenti Prog Med 1991 82 (4) 233-235
7. Feydy P, Bogomoletz W V. [A case of hepatitis caused by simvastatin]. Gastroenterol Clin Biol 1991 15 (1) 94-95
8. Spreckelsen U, Kirchhoff R, Haacke H. Chloestatischer ikterus whrend lovastatin-einnahme. Dtsch Med Wochenschr 1991 116 739-740
9. Raveh D, Arnon R, Israeli A, Eisenberg S. Lovastatin-induced hepatitis. Isr J Med Sci 1992 28 (2) 101-102
10. Grimbert S, Pessayre D, Degott C, Benhamou J-P. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci 1994 39 (9) 2032-2033
11. Huchzermeyer H, Mnzenmaier R. [Lovastatin-induced acute cholestatic hepatitis]. Dtsch Med Wochenschr 1995 120 (8) 252-256
12. Gavilán Carrasco J C., Bermdez Recio F, Salgado Ordez F, González Santos P. [Hepatitis due to lovastatin]. Med Clin (Barc) 1996 107 (14) 557-558
13. Bruguera M, Joya P, Rods J. [Hepatitis associated with treatment with lovastatin. Presentation of 2 cases]. Gastroenterol Hepatol 1998 21 (3) 127-128
14. Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol 1999 94 (5) 1388-1390
15. Jimnez-Alonso J, Osorio J M., Gutirrez-Cabello F, Lpez de la Osa A, Len L, Mediavilla Garca J D. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves. Arch Intern Med 1999 159 (15) 1811-1812
16. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet 1999 353 (9166) 1763-1764
17. Heuer T, Gerards H, Pauw M, Gabbert H E., Reis H E. Toxischer leberschaden durch HMG-CoA-reduktase-hemmer. Med Klin (Munich) 2000 95 642-644
18. Punthakee Z, Scully L J., Guindi M M., Ooi T C. Liver fibrosis attributed to lipid lowering medications: two cases. J Intern Med 2001 250 (3) 249-254
19. Graziadei I W., Obermoser G E., Sepp N T., Erhart K H., Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 2003 12 (5) 409-412
20. Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 2003 15 (8) 921-924
21. Perger L, Kohler M, Fattinger K, Flury R, Meier P J., Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol 2003 39 (6) 1095-1097
22. Gershovich O E., Lyman A E. Jr. Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature. Pharmacotherapy 2004 24 (1) 150-154
23. Wolters L MM, Van Buuren H R. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 2005 17 (5) 589-590
24. Alla V, Abraham J, Siddiqui J et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 2006 40 (8) 757-761
25. de Castro M L., Hermo J A., Baz A et al. Hepatitis colestásica aguda tras la reintroduccin atorvastatina. Gastroenterol Hepatol 2006 29 21-24
26. Famularo G, Miele L, Minisola G, Grieco A. Liver toxicity of rosuvastatin therapy. World J Gastroenterol 2007 13 (8) 1286-1288
27. Rahier J F., Rahier J, Leclercq I, Geubel A P. Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report. Acta Gastroenterol Belg 2008 71 (3) 318-320
28. Ridruejo E, Mand O G. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. J Hepatol 2002 37 (1) 165-166
29. Clarke A T., Mills P R. Atorvastatin associated liver disease. Dig Liver Dis 2006 38 (10) 772-777
30. Drug Topics. 2008 Top 200 generic drugs by total prescriptions. Available at: http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard// drugtopics/222009/599844/article.pdf Accessed May 18, 2009
31. Argo C K., Loria P, Caldwell S H., Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008 48 (2) 662-669
32. Zimmerman H J. Hepatotoxicity. 2nd ed. Philadelphia, PA Lippincott Williams & Wilkins 1999 440-444
33. Bonkovsky H L., Shedlofsky S I., Jones D P., LaBrecque D. Drug-induced liver injury In: Boyer TD, Manns MP, Wright TL Zakim and Boyer's Hepatologya Textbook of Liver Disease. 5th ed. Philadelphia, PA Saunders-Elsevier 2006 503-550
34. Boberg K M. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002 6 (3) 635-647
35. Rudski L, Rabinovitch M A., Danoff D. Systemic immune reactions to HMG-CoA reductase inhibitors. Report of 4 cases and review of the literature. Medicine (Baltimore) 1998 77 (6) 378-383
36. Purvin V, Kawasaki A, Smith K H., Kesler A. Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Medicine (Baltimore) 2006 85 (2) 82-85
37. Khosla R, Butman A N., Hammer D F. Simvastatin-induced lupus erythematosus. South Med J 1998 91 (9) 873-874
38. Ahmad S. Lovastatin-induced lupus erythematosus. Arch Intern Med 1991 151 (8) 1667-1668
39. Ricaurte B, Guirguis A, Taylor H C., Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother 2006 40 (4) 753-757
40. Kanathur N, Mathai M G., Byrd R P. Jr, Fields C L., Roy T M. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001 94 (9) 339-341
41. Caldwell S H., Hespenheide E E., von Borstel R W. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci 2001 46 (2) 376-378
42. Ashar U, Desai D, Bhaduri A. Flutamide-induced hepatotoxicity with possible potentiation by simvastatin. J Assoc Physicians India 2003 51 75-77
43. Bristol-Myers Squibb Company. Pravachol (pravastatin sodium) Tablets. Available at: http://packageinserts.bms.com/pi/pi-pravachol.pdf Accessed May 30, 2009
44. Dunn W, Xu R, Wingard D L. et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008 103 (9) 2263-2271
45. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int 2009 29 (Suppl 2) 13-25
46. Chalasani N, Aljadhey H, Kesterson J, Murray M D., Hall S D. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004 126 (5) 1287-1292
47. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005 329 (2) 62-65
48. Avins A L., Manos M M., Ackerson L et al. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. Drug Saf 2008 31 (4) 325-334
49. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008 47 (6) 2003-2009
50. Russo M W., Galanko J A., Shrestha R, Fried M W., Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004 10 (8) 1018-1023
51. Horlander J C., Kwo P Y., Cummings O W. Atorvastatin for the treatment of NASH. Gastroenterology 2001 120 A544
52. Kiyici M, Gulten M, Gurel S et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003 17 (12) 713-718
53. Rallidis L S., Drakoulis C K., Parasi A S. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004 174 (1) 193-196
54. Hatzitolios A, Savopoulos C, Lazaraki G et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004 23 (4) 131-134
55. Gmez-Domnguez E, Gisbert J P., Moreno-Monteagudo J A., Garca-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006 23 (11) 1643-1647
56. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006 184 (1) 233-234
57. Ekstedt M, Franzn L E., Mathiesen U L., Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007 47 (1) 135-141
58. Andrade R J., Lucena M I., Fernández M C. et al, Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005 129 (2) 512-521
59. Chalasani N, Fontana R J., Bonkovsky H L. et al, Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008 135 (6) 1924-1934, 1934, e1e4
60. Lewis J H., Mortensen M E., Zweig S, Fusco M J., Medoff J R., Belder R, Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007 46 (5) 1453-1463
61. Zafra C, Abraldes J G., Turnes J et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004 126 749-755
62. Trebicka J, Hennenberg M, Laleman W et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007 46 (1) 242-253
63. Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006 61 (3) 262-274
64. Hui J M., Hodge A, Farrell G C., Kench J G., Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004 40 (1) 46-54
65. Cohen D E., Anania F A., Chalasani N, National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006 97 (8A, suppl) 77C-81C